Literature DB >> 18930993

ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version.

U Kiltz1, D van der Heijde, H Mielants, E Feldtkeller, J Braun.   

Abstract

BACKGROUND: The ASAS/EULAR (Assessment of SpondyloArthritis International Society/European League Against Rheumatism) recommendations for the management of ankylosing spondylitis (AS) have been developed by rheumatologists for a target population of health professionals.
OBJECTIVE: To extend the cooperation between ASAS and EULAR by translating the recommendations into a language that can be easily understood by patients in order to further disseminate and evaluate the recommendations.
METHODS: In cooperation with patient organisations 18 patients with AS (17 European, one Canadian) were invited to attend a meeting in February 2008. As a starting point the original publication and a version created by Canadian patients with AS were used. To improve the understanding of potential problems, data on the evaluation of a recent German translation were presented. After intensive discussions the wording was adjusted and a vote was held on the new wording of the recommendations aiming for >80% agreement on each sentence. Finally, patients were asked to indicate their level of agreement with the content of the recommendations.
RESULTS: Ten recommendations were successfully translated into a patient-understandable version. The original text was changed in most cases. In all but one case (recommendation No 4) there was broad agreement with the proposed translation. The overall agreement with the content of the recommendations was high: 8.7 (0.6).
CONCLUSION: For the first time, EULAR recommendations were successfully converted into a patient-understandable language version by a large international group of patients in collaboration with rheumatologists. The evaluation showed broad agreement. Translations into different languages and further dissemination in individual countries will be performed.

Entities:  

Mesh:

Year:  2008        PMID: 18930993     DOI: 10.1136/ard.2008.096073

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  [Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

Review 2.  Ankylosis in ankylosing spondylitis: current concepts.

Authors:  Nigil Haroon
Journal:  Clin Rheumatol       Date:  2015-06       Impact factor: 2.980

3.  [ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].

Authors:  U Kiltz; J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

4.  [Recommendations for symptomatic therapy of rheumatic pain with opioid analgetics].

Authors:  W W Bolten; S Reiter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

5.  [Spondyloarthritides].

Authors:  J Braun; M Rudwaleit; J Sieper
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

Review 6.  [Spondyloarthritides].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2010-07       Impact factor: 1.372

7.  Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations.

Authors:  Ernst Feldtkeller; Gudrun Lind-Albrecht; Martin Rudwaleit
Journal:  Rheumatol Int       Date:  2013-03-29       Impact factor: 2.631

8.  [German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].

Authors:  U Kiltz; E Feldtkeller; J Braun
Journal:  Z Rheumatol       Date:  2010-03       Impact factor: 1.372

Review 9.  [Core set of behavioral recommendations for patients with ankylosing spondylitis].

Authors:  E Feldtkeller; G Lind-Albrecht; M Rudwaleit
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

10.  [The process of generating EULAR recommendations].

Authors:  M Dougados
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.